Manages mastocytosis. ANDA 202583, held by Rising Pharmaceuticals. Cromolyn Sodium.
As of Nov 21, 2026, ANDA 202583 (Cromolyn Sodium), held by Rising Pharmaceuticals, was first approved by FDA on Oct 27, 2011, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Cromolyn Sodium Oral Solution, Concentrate is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium100MG/5ML · concentrate;oral | Cromolyn Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters